{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:12:47Z","timestamp":1779883967193,"version":"3.53.1"},"reference-count":205,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,20]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Multiple myeloma (MM), a clonal plasma cell malignancy characterized by high chromosomal instability and inevitable relapse. Increased understanding of immune dysregulation and suppression during MM progression has led to the development of various immunotherapies over the past two decades. Immunotherapeutic strategies, including immunomodulatory imide drugs, monoclonal antibodies, immune checkpoint inhibitors, antibody\u2013drug conjugates, chimeric antigen receptor T cells, and bispecific T cell engagers, have been evaluated in numerous clinical trials and demonstrated significant clinical efficacy, particularly in patients with relapsed and refractory MM. However, despite these substantial advances in immunotherapy, heavily pretreated patients continue to face challenges due to limited therapeutic options and the emergence of multiple drug resistance. Therefore, it is imperative to identify new targets and develop additional treatments aimed at preventing immune escape while enhancing the efficacy of existing immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003869","type":"journal-article","created":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T01:00:29Z","timestamp":1762045229000},"page":"3404-3424","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Identification and transformation of novel targets for immunotherapy in multiple myeloma"],"prefix":"10.1097","volume":"138","author":[{"given":"Yijie","family":"Wang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghuan","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Ma","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Jing","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanting","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"},{"name":"Gobroad Healthcare Group, Beijing 100073, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Hao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"},{"name":"Gobroad Healthcare Group, Beijing 100073, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"R1-20260407","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1097\/CM9.0000000000002600","article-title":"Burden of multiple myeloma in China: An analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019","volume":"136","author":"Liu","year":"2023","journal-title":"Chin Med J"},{"key":"R2-20260407","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"R3-20260407","doi-asserted-by":"crossref","first-page":"1470328","DOI":"10.3389\/fimmu.2024.1470328","article-title":"DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"R4-20260407","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R5-20260407","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1541-7786.MCR-19-0852","article-title":"Polycomb-like protein 3 induces proliferation and drug resistance in multiple myeloma and is regulated by miRNA-15a","volume":"18","author":"Yu","year":"2020","journal-title":"Mol Cancer Res"},{"key":"R6-20260407","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","article-title":"Treatment outcomes of triple class refractory multiple myeloma: A benchmark for new therapies","volume":"36","author":"Bal","year":"2022","journal-title":"Leukemia"},{"key":"R7-20260407","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"R8-20260407","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garcia-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R9-20260407","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/CM9.0000000000003116","article-title":"Identification of potential immune-related mechanisms related to the development of multiple myeloma","volume":"137","author":"Wang","year":"2024","journal-title":"Chin Med J"},{"key":"R10-20260407","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/cancers16030498","article-title":"Novel insights into the initiation, evolution, and progression of multiple myeloma by multi-omics investigation","volume":"16","author":"Gong","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R11-20260407","doi-asserted-by":"crossref","first-page":"e1140","DOI":"10.1002\/ctm2.1140","article-title":"Multiple myeloma-derived miR-27b-3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment","volume":"13","author":"Wei","year":"2023","journal-title":"Clin Transl Med"},{"key":"R12-20260407","doi-asserted-by":"crossref","first-page":"1077768","DOI":"10.3389\/fimmu.2022.1077768","article-title":"Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"R13-20260407","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","article-title":"Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability","volume":"33","author":"Dutta","year":"2019","journal-title":"Leukemia"},{"key":"R14-20260407","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R15-20260407","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"key":"R16-20260407","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"key":"R17-20260407","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R18-20260407","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J Clin Invest"},{"key":"R19-20260407","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"R20-20260407","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"R21-20260407","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: Optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R22-20260407","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"R23-20260407","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J Immunother"},{"key":"R24-20260407","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"key":"R25-20260407","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T\u00a0cell landscape determines the response to bispecific T\u00a0cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"R26-20260407","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41375-024-02303-w","article-title":"CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma","volume":"38","author":"Ismael","year":"2024","journal-title":"Leukemia"},{"key":"R27-20260407","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2119\/molmed.2016.00198","article-title":"Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma","volume":"22","author":"Horenstein","year":"2016","journal-title":"Mol Med"},{"key":"R28-20260407","first-page":"3650","article-title":"LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma","volume":"109","author":"Gong","year":"2024","journal-title":"Haematologica"},{"key":"R29-20260407","doi-asserted-by":"crossref","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front Immunol"},{"key":"R30-20260407","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-019-1011-5","article-title":"Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation","volume":"18","author":"Ai","year":"2019","journal-title":"Mol Cancer"},{"key":"R31-20260407","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.leukres.2015.06.003","article-title":"The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR\/sCD206): Implications in multiple myeloma","volume":"39","author":"Andersen","year":"2015","journal-title":"Leuk Res"},{"key":"R32-20260407","doi-asserted-by":"crossref","first-page":"11283","DOI":"10.18632\/oncotarget.2207","article-title":"Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4\/CXCL12 axis and promote their polarization toward the M2 phenotype","volume":"5","author":"Beider","year":"2014","journal-title":"Oncotarget"},{"key":"R33-20260407","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/path.4860","article-title":"Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation","volume":"241","author":"De Beule","year":"2017","journal-title":"J Pathol"},{"key":"R34-20260407","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/leu.2012.272","article-title":"PSGL-1\/selectin and ICAM-1\/CD18 interactions are involved in macrophage-induced drug resistance in myeloma","volume":"27","author":"Zheng","year":"2013","journal-title":"Leukemia"},{"key":"R35-20260407","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00262-022-03241-1","article-title":"Interleukin-32\u03b3 promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma","volume":"72","author":"Yan","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"R36-20260407","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1084\/jem.193.6.727","article-title":"Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy","volume":"193","author":"Lin","year":"2001","journal-title":"J Exp Med"},{"key":"R37-20260407","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/leu.2017.193","article-title":"Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma","volume":"32","author":"Wang","year":"2018","journal-title":"Leukemia"},{"key":"R38-20260407","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1479-5876-10-247","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma","volume":"10","author":"Bonanno","year":"2012","journal-title":"J Transl Med"},{"key":"R39-20260407","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of melphalan in the era of modern therapies-current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J Clin Med"},{"key":"R40-20260407","first-page":"87","article-title":"Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806)","volume":"21","author":"Bergsagel","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"R41-20260407","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s12156-008-0082-0","article-title":"Historical perspective and advances in the treatment of multiple myeloma","volume":"2","author":"Harandi","year":"2008","journal-title":"Oncol Rev"},{"key":"R42-20260407","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"key":"R43-20260407","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"R44-20260407","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000206984","article-title":"Identical twin marrow transplantation in multiple myeloma","volume":"68","author":"Osserman","year":"1982","journal-title":"Acta Haematol"},{"key":"R45-20260407","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/CM9.0000000000003435","article-title":"Treatment efficacy for relapsed\/refractory multiple myeloma patients with gain\/amplification of 1q21","volume":"138","author":"Zhou","year":"2025","journal-title":"Chin Med J"},{"key":"R46-20260407","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jnci\/95.12.845","article-title":"First proteasome inhibitor approved for multiple myeloma","volume":"95","author":"Twombly","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R47-20260407","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"R48-20260407","doi-asserted-by":"crossref","first-page":"103950","DOI":"10.1016\/j.ebiom.2022.103950","article-title":"Indirubin-3\u2032-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma","volume":"78","author":"Yu","year":"2022","journal-title":"EBioMedicine"},{"key":"R49-20260407","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: Mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"R50-20260407","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"key":"R51-20260407","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"R52-20260407","doi-asserted-by":"crossref","first-page":"632399","DOI":"10.3389\/fimmu.2021.632399","article-title":"Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs","volume":"12","author":"D\u2019Souza","year":"2021","journal-title":"Front Immunol"},{"key":"R53-20260407","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41375-020-0809-x","article-title":"Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways","volume":"35","author":"Hideshima","year":"2021","journal-title":"Leukemia"},{"key":"R54-20260407","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2021014701","article-title":"Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1","volume":"139","author":"Wu","year":"2022","journal-title":"Blood"},{"key":"R55-20260407","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"key":"R56-20260407","doi-asserted-by":"crossref","first-page":"101571","DOI":"10.1016\/j.xcrm.2024.101571","article-title":"Pharmacodynamic changes in tumor and immune cells drive iberdomide\u2019s clinical mechanisms of activity in relapsed and refractory multiple myeloma","volume":"5","author":"Amatangelo","year":"2024","journal-title":"Cell Rep Med"},{"key":"R57-20260407","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2021-147812","article-title":"CC-92480, a potent, novel cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone (DEX) and bortezomib (BORT) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Preliminary results from the phase 1\/2 study CC-92480-MM-002","volume":"138","author":"Richardson","year":"2021","journal-title":"Blood"},{"key":"R58-20260407","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"R59-20260407","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): A randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"R60-20260407","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"key":"R61-20260407","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"R62-20260407","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"R63-20260407","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"R64-20260407","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: Long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"key":"R65-20260407","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"R66-20260407","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"R67-20260407","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"R68-20260407","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"R69-20260407","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"R70-20260407","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","article-title":"A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer J"},{"key":"R71-20260407","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R72-20260407","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"R73-20260407","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"R74-20260407","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: Final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"R75-20260407","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/cas.12529","article-title":"Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma","volume":"105","author":"Isoda","year":"2014","journal-title":"Cancer Sci"},{"key":"R76-20260407","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7706","article-title":"Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain","volume":"14","author":"Hasegawa","year":"2022","journal-title":"Sci Transl Med"},{"key":"R77-20260407","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R78-20260407","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-020-00350-x","article-title":"Immune-based therapies in the management of multiple myeloma","volume":"10","author":"Zanwar","year":"2020","journal-title":"Blood Cancer J"},{"key":"R79-20260407","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/ITT.S240886","article-title":"Immunotherapeutic and targeted approaches in multiple myeloma","volume":"9","author":"Nadeem","year":"2020","journal-title":"Immunotargets Ther"},{"key":"R80-20260407","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1158\/1078-0432.CCR-20-3600","article-title":"Facts and hopes in multiple myeloma immunotherapy","volume":"27","author":"Sperling","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R81-20260407","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.17448","article-title":"Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study","volume":"194","author":"Moreau","year":"2021","journal-title":"Br J Haematol"},{"key":"R82-20260407","doi-asserted-by":"crossref","first-page":"10254","DOI":"10.1002\/cam4.5753","article-title":"Isatuximab in combination with cemiplimab in patients with relapsed\/refractory multiple myeloma: A phase 1\/2 study","volume":"12","author":"Lesokhin","year":"2023","journal-title":"Cancer Med"},{"key":"R83-20260407","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/onco.13712","article-title":"Avelumab, a PD-L1 inhibitor, in combination with hypofractionated radiotherapy and the abscopal effect in relapsed refractory multiple myeloma","volume":"26","author":"Kazandjian","year":"2021","journal-title":"Oncologist"},{"key":"R84-20260407","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.clml.2024.05.014","article-title":"Nivolumab, pomalidomide, and elotuzumab combination regimens for treatment of relapsed and refractory multiple myeloma: Results from the phase 3 CheckMate 602 Study","volume":"24","author":"Oriol","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R85-20260407","doi-asserted-by":"crossref","first-page":"1085893","DOI":"10.3389\/fimmu.2023.1085893","article-title":"Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +\/- SoC in MM","volume":"14","author":"Wong","year":"2023","journal-title":"Front Immunol"},{"key":"R86-20260407","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s43018-024-00818-w","article-title":"Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: The MyCheckpoint randomized clinical trial","volume":"5","author":"Richard","year":"2024","journal-title":"Nat Cancer"},{"key":"R87-20260407","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1002\/cncr.35319","article-title":"Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma","volume":"130","author":"Suvannasankha","year":"2024","journal-title":"Cancer"},{"key":"R88-20260407","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clml.2022.10.006","article-title":"Cobimetinib alone and plus venetoclax with\/without atezolizumab in patients with relapsed\/refractory multiple myeloma","volume":"23","author":"Schjesvold","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R89-20260407","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adm7269","article-title":"Tumor extracellular vesicle-derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming","volume":"17","author":"Ma","year":"2025","journal-title":"Sci Transl Med"},{"key":"R90-20260407","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/ph16040590","article-title":"Antibody-drug conjugates for multiple myeloma: Just the beginning, or the beginning of the end?","volume":"16","author":"Ray","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R91-20260407","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.3390\/cancers15112948","article-title":"Belantamab mafodotin: From clinical trials data to real-life experiences","volume":"15","author":"Mor\u00e8","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"Suppl 2","key":"R92-20260407","first-page":"S22","article-title":"Antibody drug conjugates for the treatment of multiple myeloma","volume":"98","author":"Leong","year":"2023","journal-title":"Am J Hematol"},{"key":"R93-20260407","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"R94-20260407","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Final analysis of the DREAMM-2 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"key":"R95-20260407","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): A phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"R96-20260407","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"R97-20260407","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"R98-20260407","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"R99-20260407","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/10428194.2024.2373331","article-title":"Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma","volume":"65","author":"Dimopoulos","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"R100-20260407","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1078-0432.CCR-19-1431","article-title":"First-in-human phase I study of ABBV-838, an antibody-drug conjugate targeting SLAMF7\/CS1 in patients with relapsed and refractory multiple myeloma","volume":"26","author":"Vij","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R101-20260407","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"key":"R102-20260407","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","article-title":"HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells","volume":"20","author":"Figueroa-Vazquez","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"R103-20260407","doi-asserted-by":"crossref","first-page":"CT067","DOI":"10.1158\/1538-7445.AM2024-CT067","article-title":"Abstract CT067: The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising initial first in human results in relapsed multiple myeloma","volume":"84","author":"Kaufman","year":"2024","journal-title":"Cancer Research"},{"key":"R104-20260407","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-024-01611-z","article-title":"Targeting GPRC5D for multiple myeloma therapy","volume":"17","author":"Zhou","year":"2024","journal-title":"J Hematol Oncol"},{"key":"R105-20260407","doi-asserted-by":"crossref","first-page":"2000.2002","DOI":"10.1182\/blood-2024-207816","article-title":"A Phase I\/II study of AZD0305, a novel antibody-drug conjugate (ADC) targeting GPRC5D, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"144","author":"Lim","year":"2024","journal-title":"Blood"},{"key":"R106-20260407","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1158\/1538-7445.AM2022-6020","article-title":"Abstract 6020: Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma","volume":"82","author":"Huang","year":"2022","journal-title":"Cancer Res"},{"key":"R107-20260407","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1182\/blood-2021-150783","article-title":"A Phase 1, open-label, dose-escalation study of the safety and efficacy of anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"R108-20260407","doi-asserted-by":"crossref","first-page":"e70039","DOI":"10.1002\/hem3.70039","article-title":"Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma","volume":"8","author":"Bruins","year":"2024","journal-title":"Hemasphere"},{"key":"R109-20260407","doi-asserted-by":"crossref","first-page":"12621","DOI":"10.1182\/blood-2022-168960","article-title":"A Phase 1, open-label, dose-escalation and expansion, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of MT-0169 in patients with relapsed or refractory multiple myeloma or non-hodgkin lymphoma","volume":"140","author":"Dholaria","year":"2022","journal-title":"Blood"},{"key":"R110-20260407","first-page":"A475","article-title":"447\u2005Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma","volume":"9","author":"Kumar","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R111-20260407","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S2152-2650(21)02352-1","article-title":"P-225: A first-in-human study of FOR46 in patients with triple refractory multiple myeloma","volume":"21","author":"Wong","year":"2021","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"R112-20260407","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14712598.2020.1802422","article-title":"Antibody-drug conjugates for multiple myeloma","volume":"21","author":"McMillan","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R113-20260407","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood.V128.22.4470.4470","article-title":"SGN-CD48A: A novel humanized anti-CD48 antibody-drug conjugate for the treatment of multiple myeloma","volume":"128","author":"Lewis","year":"2016","journal-title":"Blood"},{"key":"R114-20260407","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"R115-20260407","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"R116-20260407","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"R117-20260407","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): A single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"key":"R118-20260407","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma","volume":"9","author":"Yu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R119-20260407","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"R120-20260407","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"R121-20260407","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol Ther"},{"key":"R122-20260407","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: Post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"key":"R123-20260407","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"R124-20260407","doi-asserted-by":"crossref","first-page":"e005145","DOI":"10.1136\/jitc-2022-005145","article-title":"Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"10","author":"Qu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R125-20260407","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"R126-20260407","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"R127-20260407","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"key":"R128-20260407","doi-asserted-by":"crossref","first-page":"e009476","DOI":"10.1136\/jitc-2024-009476","article-title":"BCMA-BBZ-OX40 CAR-T therapy using an instant manufacturing platform in multiple myeloma","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R129-20260407","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"key":"R130-20260407","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"R131-20260407","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"key":"R132-20260407","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol"},{"key":"R133-20260407","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R134-20260407","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"R135-20260407","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"key":"R136-20260407","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"key":"R137-20260407","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R138-20260407","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"R139-20260407","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"R140-20260407","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"R141-20260407","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"R142-20260407","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"R143-20260407","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"R144-20260407","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"R145-20260407","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: Updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"R146-20260407","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA approval summary: Ciltacabtagene autoleucel for relapsed or refractory multiple myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R147-20260407","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17460441.2024.2319672","article-title":"The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma","volume":"19","author":"Strassl","year":"2024","journal-title":"Expert Opin Drug Discov"},{"key":"R148-20260407","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"R149-20260407","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"R150-20260407","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, Open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"key":"R151-20260407","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b-2, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol"},{"key":"R152-20260407","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"R153-20260407","doi-asserted-by":"crossref","first-page":"215949","DOI":"10.1016\/j.canlet.2022.215949","article-title":"BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"553","author":"Yang","year":"2023","journal-title":"Cancer Lett"},{"key":"R154-20260407","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","article-title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: A report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"key":"R155-20260407","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric antigen receptor T cell therapy for myeloma: Where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R156-20260407","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of Parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"R157-20260407","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41571-025-00996-1","article-title":"International approvals of cilta-cel: A lens on CAR T cell regulation","volume":"22","author":"Ge","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R158-20260407","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"R159-20260407","article-title":"Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed\/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cells","author":"Chen","year":"2024","journal-title":"Chin Med J"},{"key":"R160-20260407","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol"},{"key":"R161-20260407","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40291-023-00673-y","article-title":"Equecabtagene autoleucel: First approval","volume":"27","author":"Keam","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"R162-20260407","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"R163-20260407","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMc2308544","article-title":"Genetic basis of relapse after GPRC5D-targeted CAR T cells","volume":"389","author":"Mi","year":"2023","journal-title":"N Engl J Med"},{"key":"R164-20260407","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"R165-20260407","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"key":"R166-20260407","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"R167-20260407","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-20-0118","article-title":"Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity","volume":"8","author":"Globerson Levin","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"R168-20260407","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1158\/1078-0432.CCR-23-0132","article-title":"Specific targeting of multiple myeloma by dual split-signaling chimeric antigen receptor T cells directed against CD38 and CD138","volume":"29","author":"van der Schans","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R169-20260407","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"key":"R170-20260407","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am J Pathol"},{"key":"R171-20260407","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"R172-20260407","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"R173-20260407","doi-asserted-by":"crossref","first-page":"e006699","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R174-20260407","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"key":"R175-20260407","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat Commun"},{"key":"R176-20260407","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3324\/haematol.2010.036814","article-title":"Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma","volume":"96","author":"Atanackovic","year":"2011","journal-title":"Haematologica"},{"key":"R177-20260407","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat Commun"},{"key":"R178-20260407","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add7900","article-title":"Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity","volume":"15","author":"Vander Mause","year":"2023","journal-title":"Sci Transl Med"},{"key":"R179-20260407","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/1541-7786.MCR-20-0622","article-title":"ILT3 (LILRB4) Promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells","volume":"19","author":"Singh","year":"2021","journal-title":"Mol Cancer Res"},{"key":"R180-20260407","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"R181-20260407","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol Ther"},{"key":"R182-20260407","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13046-024-03110-y","article-title":"LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2\/NF-\u03baB\/RELT signal pathway","volume":"43","author":"Wang","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"R183-20260407","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41419-024-06883-4","article-title":"LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway","volume":"15","author":"Xie","year":"2024","journal-title":"Cell Death Dis"},{"key":"R184-20260407","doi-asserted-by":"crossref","first-page":"101374","DOI":"10.1016\/j.xcrm.2023.101374","article-title":"Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep Med"},{"key":"R185-20260407","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","article-title":"New biological therapies for multiple myeloma","volume":"75","author":"Garfall","year":"2024","journal-title":"Annu Rev Med"},{"key":"R186-20260407","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/hematology.2019000068","article-title":"Myeloma: next generation immunotherapy","volume":"2019","author":"Cohen","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R187-20260407","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: Overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R188-20260407","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"R189-20260407","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"R190-20260407","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"R191-20260407","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"R192-20260407","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1\u20132 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"R193-20260407","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"R194-20260407","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"key":"R195-20260407","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.2024025987","article-title":"Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma","volume":"145","author":"Eckmann","year":"2025","journal-title":"Blood"},{"key":"R196-20260407","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"key":"R197-20260407","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1182\/blood-2023-177968","article-title":"Patterns of response to 200 mg linvoseltamab in patients with relapsed\/refractory multiple myeloma: Longer follow-up of the linker-MM1 study","volume":"142","author":"Jagannath","year":"2023","journal-title":"Blood"},{"key":"R198-20260407","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood-2024-199733","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma: Longer follow-up and selected high-risk subgroup analyses of the linker-MM1 study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"R199-20260407","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"key":"R200-20260407","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"R201-20260407","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"R202-20260407","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"R203-20260407","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.2024025987","article-title":"Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma","volume":"145","author":"Eckmann","year":"2024","journal-title":"Blood"},{"key":"R204-20260407","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","article-title":"Just scratching the surface: Novel treatment approaches for multiple myeloma targeting cell membrane proteins","volume":"21","author":"Neri","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"R205-20260407","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: Latest updates from ASCO 2023 Annual Meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:02:48Z","timestamp":1775592168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":205,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003869","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2025-03-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}